International Assets Investment Management LLC Takes Position in Sanofi (NASDAQ:SNY)

International Assets Investment Management LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 122,118 shares of the company's stock, valued at approximately $7,038,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Stablepoint Partners LLC boosted its holdings in Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company's stock valued at $1,377,000 after purchasing an additional 189 shares in the last quarter. TCTC Holdings LLC boosted its stake in Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company's stock valued at $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC grew its position in Sanofi by 3.7% in the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company's stock valued at $299,000 after acquiring an additional 221 shares during the period. Insigneo Advisory Services LLC raised its stake in Sanofi by 3.3% during the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company's stock worth $371,000 after acquiring an additional 228 shares in the last quarter. Finally, Pinnacle Bancorp Inc. lifted its holdings in shares of Sanofi by 24.6% during the third quarter. Pinnacle Bancorp Inc. now owns 1,227 shares of the company's stock valued at $71,000 after acquiring an additional 242 shares during the period. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SNY shares. Argus boosted their target price on Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, StockNews.com upgraded shares of Sanofi from a "buy" rating to a "strong-buy" rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $57.50.

Sanofi Stock Up 0.7 %

SNY traded up $0.39 during trading on Friday, reaching $53.27. The company had a trading volume of 1,381,542 shares, compared to its average volume of 2,035,988. The company has a market cap of $135.19 billion, a P/E ratio of 26.98, a PEG ratio of 1.36 and a beta of 0.60. Sanofi has a 12 month low of $45.00 and a 12 month high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business's fifty day moving average price is $55.98 and its 200 day moving average price is $51.91.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the previous year, the company posted $2.55 earnings per share. The company's quarterly revenue was up 12.3% compared to the same quarter last year. Equities analysts anticipate that Sanofi will post 4.27 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.